Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis

Leukemia & Lymphoma
Yongbin YeKunyuan Guo

Abstract

Acute myeloid leukemia (AML) is a common disorder in the elderly. Although remarkable progress has been made over recent decades, the outcome remains poor. Thus, the development of a more effective method to overcome this problem is necessary. In this study, we aimed to investigate the synergistic cytotoxic effect of low-dose arsenic trioxide (As2O3) combined with aclacinomycin A (ACM) on the human AML cell lines KG-1a and HL-60, and to clarify the underlying mechanism. Results showed that As2O3 combined with ACM exerted a synergistic cytotoxic effect by activation of the apoptosis pathway. Additionally, we found that the combination treatment decreased Bcl-2, c-IAP and XIAP expression but increased SMAC and caspase-3 expression more significantly than the single drug treatments. Furthermore, combination index (CI) values were < 1 in all matched combination groups. Additional evaluation of As2O3 combined with ACM as a potential therapeutic benefit for AML seems warranted.

References

Oct 1, 1975·The Journal of Antibiotics·T OkiI Kitamura
Sep 15, 1992·Biochimica Et Biophysica Acta·T IsoeT Tsuruo
Sep 1, 1986·Journal of Clinical Pharmacology·S WadlerP H Wiernik
Nov 14, 1997·Chemical & Pharmaceutical Bulletin·K Utsuno, M Tsuboi
Nov 5, 1998·The New England Journal of Medicine·S L SoignetR P Warrell
Apr 6, 1999·The Journal of Experimental Medicine·V Lallemand-BreitenbachH de Thé
Jul 31, 2003·Pharmacology & Therapeutics·Annette K LarsenAndrzej Skladanowski
Dec 23, 2003·Cancer Biology & Therapy·A-C GouletMark A Nelson
Mar 17, 2004·Oncogene·Huang-Ge ZhangJohn D Mountz
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
Jul 18, 2008·Nature·Jan M SkotheimFrederick R Cross
Apr 18, 2009·Toxicology and Applied Pharmacology·Yi-Chen WuLing-Huei Yih
May 27, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bach ArdalanParvin Ganjei-Azar
Aug 28, 2010·Journal of Hematology & Oncology·Clement YedjouRobert McMurray
Apr 13, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ling-Huei YihYi-Chen Wu
Dec 18, 2013·The Journal of Experimental Medicine·Guilherme Augusto Dos SantosPier Paolo Pandolfi

❮ Previous
Next ❯

Citations

Oct 28, 2015·Experimental Hematology·Hebing ZhouWenming Chen
May 6, 2015·Leukemia & Lymphoma·Dennis J Goussetis, Leonidas C Platanias

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.